Edit: I should contextualise this by noting I have basically no experience with pharma so grain of salt blah blah
My main point is that drug development is more expensive than most realize. Beyond R&D, a lot of that cost is in postmarketing (after approval) safety studies and surveillance- to catch side effects not observed in clinical trials. This process can be made somewhat more efficient as you suggested, but at the end of the day a human is reviewing every side effect report and reporting those back to regulatory agencies etc.
I am not qualified to discuss the economics re: your point on pharma r&d - drug discovery is it’s own thing aside from actual drug development.
The basic assummption in cryptography is “assume the target system is already compromised” so i would wager you are partially correct. Its just that its not the whole story, especially if u think that private persons get massssive discounts if they try to privately pay (from reading below comments about quotes to insurance companies vs private people).
Its a sad dynamic thats probably ruining more loves than it should.
> "The median per-drug R&D spending of companies that developed more than six drugs – that’s only 8 companies – was $5.8 billion."
...so that is $5-6B USD per drug DEVELOPED in large companies.
Gilead - maker of Sovaldi/Harvoni for HepC treatment - has been on a development tear of late, and almost certainly falls into that range IMO [2].
For companies that produce fewer drugs - the estimates are between $700M-$1B per drug.
Note these are prices for drug R&D only ("development") - there is no guarantee those drugs developed make it to market ("approval") - Over 90% do not.
edit: source links
1 - https://www.forbes.com/sites/matthewherper/2017/10/16/the-co...
2 - https://en.wikipedia.org/wiki/Gilead_Sciences#2010_to_2019